Audentes Therapeutics, Inc. (BOLD)
BOLD Price and Sentiment
BOLD Latest news
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
Find out how strategic moves helped a couple of these stocks.
Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details.
Japanese company Astellas Pharma is acquiring gene therapy biotech company Audentes Therapeutics for $3 billion, the companies said late Monday.
4 newborns diagnosed with XLMTM no longer require a ventilator after being treated with BOLD's AT-132.
Audentes Therapeutics, Inc. (BOLD) CEO Matt Patterson on Q2 2019 Results - Earnings Call Transcript
Shares have risen by over 130% since my initial recommendation.
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
CNBC's "Power Lunch" team discusses potential biotech buys focused on gene therapy with Andrew Bary, associate editor of Barron's.